B cell chronic lymphocytic leukemia (B-CLL) is a chronic leukemia manifested by increased numbers of B cells in circulation. The slow, smouldering nature of the disease in a significant proportion of the cases makes it an ideal target for immunotherapy. Dendritic cell (DC)-based immunotherapy is emerging as an exciting modality with significant clinical potential. In this study, three strategies for delivering antigens to DC, namely apoptotic bodies (Apo-DC), tumor lysates, and tumor RNA were studied in an autologous setting. In all six CLL patients, Apo-DC induced higher HLA-restricted, T cell responses than DC pulsed with tumor lysate or RNA. Real-time PCR confirmed higher expression of genes for IL-2 and IFN-c in T cells stimulated with Apo-DC. Concurrently, no IL-10 and low IL-4 responses indicated that the immune response was primarily of the Th1 type. Enzyme-linked immunospot assay revealed high IFN-c secretion by T cells when Apo-DC was used to stimulate autologous T cells in all patients. Our data suggest that cellular vaccines with DC loaded with apoptotic bodies may be a suitable approach for immunotherapy of B-CLL.
Introduction
B cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of a clone of malignant B cells in lymphoid tissues, bone marrow, and peripheral blood. B-CLL is a clonal B cell neoplasm, with morphologically mature, functionally immature CD5 þ B cells that express IgM and IgD molecules on cell surface. 1 The disease predominantly occurs in the elderly, which restricts the use of chemotherapy due to its regimen-related toxicity. Moreover, although chemotherapy can induce partial or complete remission, 2 long-term symptom-free survival is unusual once treatment is needed. In view of the fact that in most cases, disease progression occurs over months or years, immune intervention appears to be a promising approach for the therapy of B-CLL. 3 It is now established that dendritic cells (DC) may serve as potent cellular adjuvants for tumor immunotherapy due to their unique ability to take up, process, and present antigens in a highly efficient manner 4 and play a pivotal role in the initiation of T cell-mediated immune responses. 5 Large numbers of DC required for clinical therapy can be generated in vitro by culturing peripheral blood monocytes in the presence of GM-CSF and IL-4. 6 A critical issue in optimizing DC vaccines is choosing the proper source and subtype of DC as well as the source of tumor antigen(s). Clinical vaccination trials for patients with malignant melanoma have demonstrated that vaccinating against a single antigen can induce tumor-specific CTLs but carries the risk of promoting tumor antigen escape variants. 7 To circumvent this limitation, whole tumor cells containing multiple known, as well as yet unidentified antigens, may be a superior source of tumor antigens. In this regard, tumor cell-DC fusion, loading DC with apoptotic bodies and tumor lysate 8 and pulsing DC with tumor cell RNA 9 may be suitable methods of loading DC with antigens.
This study was performed to compare tumor cell-derived total RNA, unfractionated tumor lysate or apoptotic tumor cells as sources of TAA for priming leukemia-specific immune responses. Additionally, we have also examined the efficacy of uptake of apoptotic bodies, tumor cell-derived RNA, and tumor lysate 9 by DC.
Materials and methods

Patients
Peripheral blood was collected from patients and normal volunteers with informed consent according to a protocol approved by the institutional ethical committee and in keeping with the Helsinki declaration on research on human subjects. Six B-CLL patients (three male and three female subjects) with a mean age of 65 years were studied. The diagnostic and staging criteria as well as criteria for progressive and nonprogressive disease have been described earlier. 10, 11 Five patients were at Rai stage 0, and one (patient 6) was at stage 1. All patients had nonprogressive disease and had not received any previous therapy. Three healthy control donors with a mean age of 63 years were also included in this study.
Generation of dendritic cells
DC was generated from CD14 þ precursors as previously described. 6 Briefly, CD14 þ monocytes were immunomagnetically enriched from PBMC obtained by Ficoll separation of peripheral blood. The starting purity of the monocytes was 93.372% (mean7s.e.m.) as measured by flow cytometry. CD14 þ cells were cultured with recombinant granulocytemacrophage colony stimulating factor (rGM-CSF) (50 ng/ml) (Schering-Plough Research Institute (SPRI), Kenilworth, NJ, USA) and recombinant interleukin IL-4 (SPRI; 10 ng/ml) for 5 days. For maturation of DC, recombinant tumor necrosis factor (rTNF-a, Pharmingen, San Diego, CA, USA; 20 ng/ml) and polyriboinosinic polyribocytidylic acid (poly I:C; 50 mg/ml, Sigma, St Quentin Fallavier, France) were added on Day 5 and then further cultured for 2 days. Cells with typical morphology of DC and CD3
þ were defined as DC as described earlier.
B cell and T cell purification B cell and T cell purification and induction of apoptosis was performed as previously described. 6 Detailed procedures are included as supplementary information accompanying the paper.
Immunophenotyping
Cells were analyzed by flow cytometry using conjugated anti CD3, CD5, CD14, CD80, CD86, and MHC II monoclonal antibodies (MAb) and isotype-matched negative control MAb (Becton-Dickinson, Mountain View, CA, USA). CD19, CD1a and CD83 MAb were obtained from DAKO A/S (Glostrup, Denmark). Surface marker staining was performed according to the method described earlier. 6 In all, 0.5-1 Â 10 6 purified cells were stained with fluorochrome-conjugated MAb or isotypematched labeled antibodies. Cells were incubated on ice for 20 min followed by twice washing with ice-cold PBS and analyzed using a FACScan flow cytometer and the CELLQuest analysis software (Becton-Dickinson).
Preparation of tumor cell lysate
Purified CLL and normal B cells were resuspended at a density of 4 Â 10 7 /ml in a serum-free medium and subjected to four freeze-thaw cycles by alternating between dry ice and 371C. The lysate was centrifuged for 10 min at 300 g to remove debris and the supernatant was collected. The protein concentration of the lysate was determined by a commercial assay (Bio-Rad, Munich, Germany). The lysate was added to autologous immature DC at a final concentration of 120 mg of protein/ml. 4 h after adding tumor lysate to the DC, Poly I:C and TNF-a were added and maturation of DC was allowed for 48 h.
Transfection of DC with autologous tumor cell RNA RNA transfection to DC was performed as described earlier. 9 Total RNA was extracted from 8 Â 10 7 tumor cell and the RNA was dissolved in X-VIVO 10 medium (Bio-Whittaker, Walkersville, MD, USA) and stored at À701C. RNA concentration was measured using a UV spectrophotometer (Shimadzu, Kyoto, Japan). The integrity of RNA from CLL and normal B cells was assessed by agarose gel electrophoresis. DC were washed once with serum-free media and resuspended in X-VIVO 10 and placed on ice. In total, 1 million DC were mixed with 25 mg RNA in 0.2 ml X-VIVO 10 medium. The mixture was transferred to a 2-mm gap (distance between the electrodes in the cuvette used for electroporation) and pulsed with a square-wave electroporator at 800 V for 0.25 ms. After incubation on ice for 1 min, the cells were washed with a serum-free medium and resuspended in complete medium. RNA-pulsed DC were matured for an additional 48 h with TNFa and poly I:C prior to use in experiments. To establish the uptake and translation of the electroporated RNA, DC were pulsed with purified enhanced green fluorescent protein (EGFP) mRNA under identical conditions and expression of EGFP was evaluated by FACS analysis.
Apoptotic tumor cell uptake by DC
Apoptotic B-CLL cells were added to immature DC at a ratio of 1:2. Uptake of apoptotic bodies occurred at over 4 h of coculture following which DC were activated with TNF-a and poly I:C for 48 h. In some experiments apoptotic bodies were labeled with the fluorescent membrane dye PKH-67 and the DC with PKH-26 as per the manufacturer's instructions (Sigma). Dual-positive cells were quantitated using flow cytometry to assess the number of DC that had endocytosed apoptotic bodies. DC with internalized apoptotic cells, as described, has been referred to as Apo-DC.
Fluorescein isothiocyanate (FITC)-conjugation and measurement of tumor lysate uptake by DC Tumor cell lysate was mixed with 10 mg/ml FITC solution and incubated overnight at 41C. The FITC-protein mixture was dialyzed using a dialysis filter, with a 3500 molecular weight cutoff (MWCO) (Spectrom, CA, USA) against buffer for 24 h. 13 The protein concentration of the FITC-conjugated lysate was determined by a commercial assay (Bio-Rad, Munich, Germany) and the conjugate was added to immature DC at a final concentration of 120 mg of protein/ml. Fluorescence of FITC bound to the DC surface was quenched with trypan blue (TB 0.5 mg/ml in Tris Hanks buffer) added to the cell suspension prior to flow cytometry. Unpulsed DC were used as negative control.
T cell proliferation assay
T cell proliferation was measured as previously described. 6 The detailed procedure has been provided in the supplementary information accompanying the paper. Proliferative responses of autologous T cells from normal, age-matched donors induced by Apo-DC, DC-lysate and DC-RNA, using autologous, normal B cells as the antigen source, were also examined (n ¼ 2).
MHC class I and II blocking
In certain experiments, DC were incubated with 10 mg/ml MAbs against HLA-II (DP, DQ, DR, clone; CR3/43; and HLA-A, B, C clone W 6/32, Dako) for 30 min at 41C before the addition of T cells. The MAbs were present throughout the culture period. Irrelevant MAbs were used as isotype controls. DNA synthesis was measured after 5 days of culture with a pulse of 1 mCi 
Enzyme-linked immunospot assay (ELISPOT)
Identification of IFN-g-secreting T cells was performed as described earlier.
14 The detailed procedure has been provided as supplementary information accompanying the paper.
RNA extraction and cDNA synthesis and real-time PCR
The detailed procedure for measuring cytokine mRNA by realtime PCR and the sequences of the primers has been provided in the supplementary information accompanying the paper.
Results
The efficiency of various approaches to load antigen into DC and the ability of the antigen-loaded DC to stimulate autologous, antitumor, T cell responses was investigated in this DC-based vaccines in B-CLL P Kokhaei et al study. One of the criteria appraised was the extent to which the antigen was taken up by the DC. The second criteria was the magnitude and nature of the T cell response stimulated by Apo-DC, DC-lysate, and DC-RNA, as measured by the proliferation assay, ELISPOT, and real-time PCR.
Immunophenotyping
Separation of B cells using nylon wool yielded a purity of 89-95% (91.371.4) CD19 þ B cells in the six B-CLL patients. The purity of monocytes selected immunomagnetically, (CD14 þ ) ranged from 92-98% (9372). DC was generated from peripheral blood monocytes of B-CLL patients and healthy control donors. DC displayed the characteristic morphology and phenotype with the expression of CD83 and lack of CD14 (o1% were CD14 þ ) in CLL patients as well as in healthy control donors. Morphological characteristics of Apo-DC, DClysate and unpulsed DC were assessed using surface marker staining and flow cytometry (Table 1) . Results represent the mean7s.e.m. of four separate experiments and depict the percentage of gated live cells expressing a particular marker. A minor increase in the expression of CD80 was noted following the endocytosis of apoptotic bodies by DC. Other than the difference in CD80 expression, no other alteration in phenotypic markers was noted in the DC loaded with antigen by the different methods.
Apoptotic bodies and DC, fluorescently labeled with PKH dyes, were cocultured as described in Materials and methods. Dual-positive cells were measured by flow cytometry to assess the rate of apoptotic tumor cell uptake by DC. Flow cytometric analysis showed that 86% of DC had endocytosed apoptotic tumor cells as shown in Figure 1 .
Uptake of FITC-conjugated tumor lysate was measured by flow cytometry after incubation of DC with FITC-lysate for 4 h at 371C. Unpulsed DC of the same patient or healthy volunteer was used to set the threshold fluorescence value. Approximately 97% of the DC demonstrated increased green fluorescence compared to control following incubation with FITC-lysate ( Table 2 ). On addition of TB, which quenches fluorescence of FITC, no significant reduction in the number of fluorescent cells was noted. The results suggest that the FITC-labeled lysate was truly endocytosed, rather than associated with the surface of the DC.
Total RNA was purified from CLL cells as described in Materials and methods. The integrity of the RNA was confirmed by gel electroporesis prior to use for transfecting DC. Electroporation conditions were standardized using pure eGFP RNA, 48 h after electroporation with eGFP RNA, flow cytometric analysis demonstrated that 19% of the DC expressed GFP protein.
Proliferation of autologous T cells following stimulation with antigen-loaded DC
DC loaded with apoptotic bodies, tumor RNA, or tumor lysate were used to stimulate autologous T cell responders in a proliferation assay. DC loaded with apoptotic bodies were the only stimulators that consistently induced T cell proliferation significantly greater than that induced with unpulsed DC (Figure 2) . Neither lysate-pulsed DC nor DC loaded with tumor RNA could significantly and consistently induce autologous T cell proliferation greater than that observed with unpulsed DC (Figure 2 ). Apo-DC generated from DC and B cells of healthy volunteers demonstrated significantly lower autologous T cell proliferation, as shown by the broken horizontal line. Thus, the T cell proliferation induced by Apo-DC was specifically associated with cells of B-CLL patients and did not occur when normal nonleukemic cells were used. Addition of antibodies against MHC class I or class II brought about a significant inhibition of autologous T cell proliferation (Figure 3) . The percentage inhibition noted on the Y-axis represents the extent to which cultures treated with antibodies against MHC class I or class II were inhibited, compared to those treated with an isotype control. It is known that MHC restriction is a hallmark of antigen-specific responses and that CD4 þ cells recognize antigens in conjunction with MHC class II, whereas CD8 þ cells recognize antigen in conjunction with MHC class I. The inhibition of T cell proliferation by both anti-class I and class II antibodies in our experiments demonstrate that the T cell response was against antigens of the B-CLL cells rather than a nonspecific, cytokine-induced proliferation.
IFN-g production in response to Apo-DC, DC-lysate, and DC-RNA
In addition to overall T cell proliferation, we also utilized a single-cell assay, that is, IFN-g ELISPOT to compare the frequency of T cells stimulated by each category of antigenloaded DC. As depicted in Figure 4 , Apo-DC stimulated a significantly higher frequency of IFN-g-secreting T cells in comparison to DC-lysate and DC-RNA. With regard to the other methods of antigen loading, a minor increase in the number of IFN-g-producing T cells were noted on stimulation with DClysate, whereas DC-RNA failed to induce a significant increase in IFN-g-producing T cells compared to unpulsed DC. As noted with the results of the T cell proliferation assay, Apo-DC generated from normal volunteers did not stimulate IFN-g responses against autologous, normal B cells (represented by the dashed line in Figure 4 ).
Cytokine and cytotoxic proteins gene expression
It is generally believed that effective antitumor immunity is associated with a Th1 rather than a Th2 type immune response. 15 Th1 cells are known to produce cytokines like IFN-g and TNF-a, whereas Th2 cells produce cytokines like IL-4 and IL-10. To study the nature of the T cells stimulated by the various antigen-loaded DC, semiquantitative real-time PCR was performed to measure the mRNA for various cytokines in the T cells following DC stimulation. The results of real-time PCR analysis for IL-2, IL-4, IL-10, IFN-g, TNF-a, and perforin are summarized in Figure 5 . Perforin was induced equally well by all the three types of stimulation. High levels of IFN-g and TNF-a were noted in T cells stimulated with Apo-DC. Concurrently, low levels of IL-4 and a complete absence of IL-10 were observed, suggesting that Apo-DC stimulation resulted in a polarization towards the Th1 subtype of response.
Discussion
To our knowledge, this is the first report that compares three alternative strategies of loading antigen from whole tumor cells into DC for CLL immunotherapy. Another novel finding of this study is that stimulation of autologous T cells by Apo-DC polarizes the immune response towards a Th1 subtype. Several clinical studies have been reported using DC as vaccine in cancer immunotherapy. [16] [17] [18] However, the optimum method of loading antigen into DC remains unclear and may vary in relation to the target antigen and the type of malignancy. Effect of anti-MHC class I and II antibodies on proliferation of T cells. DC loaded with antigens were incubated with 10 mg/ml of monoclonal antibodies against MHC class I or II or an isotype control. They were then used to stimulate autologous T cells in an in vitro assay of T cell proliferation, as described in the previous figure. Antibodies were presented throughout the period of the assay. Percentage inhibition was calculated in relation to [ Frequency of IFN-g-secreting T cells stimulated by antigen-loaded DC as measured by ELISPOT. Autologous T cells were incubated overnight with antigen-loaded DC at a ratio of 10:1. They were then added to 96 wells precoated with anti-IFN-g antibody and cultured for 1 day. Biotinylated anti-IFN-g antibody, avidin-conjugated alkaline phosphatase, and BCIP were used to develop a color reaction. Spots were counted using an automatic ELISPOT reader. In other experiments, DC generated from healthy volunteers were loaded with apoptotic, autologous B cells and used to stimulate autologous T cells. The mean number of IFN-g -producing T cells from these healthy volunteers (n ¼ 2) is shown as the dashed horizontal line.
Loading DC with a diverse array of tumor antigens would lessen the chances for tumor escape. DC efficiently present the dominant epitopes that are restricted to the patient's MHC genotype and the resulting MHC-peptide complexes can be rather stable at the cell surface with half lives of 24 h. 19 In this study, we investigated the ability of monocyte-derived DC pulsed with three different B-CLL tumor cell preparations to induce an antitumor T cell response. The result showed that Apo-DC is more potent than DC-lysate and DC-RNA in inducing T cell priming and activation. This was evidenced by enhanced proliferative responses, frequency of IFN-g-secreting cells, and a polarization of the responding T cells towards the Th1 subtype. This result is in agreement with a report from Hoffman et al, 20 who reported that human DC that had endocytosed apoptotic tumor cell line (PCI-13) were more potent than lysate-pulsed DC in generating tumor-specific T cells. Our results showed the level of IFN-g gene expression, which has been know as a Th1 cytokine, in the T cells stimulated by Apo-DC was greater than in T cells stimulated by DC-lysate or DC-RNA. Kotera et al 21 have reported higher IL-12 production by DC loaded with apoptotic tumor cells in an animal model where they have analyzed necrotic and apoptotic tumor cells as a source of antigens in dendritic cell-based immunization. 21, 22 Higher IL-12 production can polarize T cells toward Th1-type immune response. 23 Moreover, the antitumor effector activity required the participation of CD4 þ and CD8 þ T lymphocytes. 24 Our result showed that Apo-DC is more potent than DC-lysate or DC-RNA in inducing, T cell immune responses and that all of these methods of loading whole tumor antigens stimulate both CD4 þ and CD8 þ T cells. This was evidenced by enhanced MHC I, and MHC II MAb blocking in proliferation assay. We have also noticed that perforin mRNA, which indicates cytotoxic potential, is expressed equally well by three different methods of antigen loading. Concordant to these results, Schnurr et al 8 have previously reported that tumor vaccines consisting of DC and apoptotic tumor cells may be able to activate CTLs, as well as effector cells of the innate immune system. Recently, Kenneth C Anderson et al have pulsed DC with apoptotic bodies and cell lysate from multiple myeloma (MM) patients and used these DC as APC for stimulating autologous T cells. In this study, DC pulsed with MM apoptotic bodies were more effective at inducing CTLs against autologous MM cells than DC pulsed with MM cell lysates, which is congruent with our findings in CLL. 25 The effect of apoptotic bodies on DC maturation remains to be established. In our studies, no significant difference in phenotypic markers was observed in the DC loaded with antigens by the different methods. Our results are in keeping with the studies by Kotera et al 21 who report that the uptake of apoptotic bodies did not affect DC maturation. These are in contrast to the report by Ishii et al 26 demonstrating the induction of DC maturation following uptake of UV light-induced apoptotic bodies. The nature of the apoptotic cells and the purity of the DC preparation may account for the inconsistency in observations, since other phagocytes contaminating the DC population may secrete soluble factors on ingesting apoptotic bodies, which in turn may have an effect on DC maturation.
In our experiments, uptake of apoptotic normal B cells by autologous DC from healthy volunteers did not stimulate an immune response. This implies that the autologous immune response was CLL associated and could not be elicited as readily with normal B cells. However, the experiments do not provide definitive proof that the immune responses stimulated by the Apo-DC are indeed restricted to the B-CLL cells. The high circulating numbers of B-CLL in the peripheral blood of the patients in this study makes it virtually impossible to isolate sufficient numbers of normal B cells for use as controls. Nevertheless, we are currently investigating the TCR repertoire of the antileukemic T cells with the aim to delineate the antigen(s) against which the immune responses may be directed.
The CD80 molecule was expressed on a slightly higher percentage of Apo-DC in comparison to DC loaded with tumor lysate. The cause for this increase is not clear and may possibly be due to factors induced in the B-CLL cells during apoptosis. This increase may be one possible explanation why Apo-DC serve as better APC although it is hard to conceive that this comparatively minor increase in CD80 is responsible for all of the observed effects, including an increased g-IFN response and a complete absence of IL-4 secretion by Apo-DC-stimulated, autologous T cells. It is still unclear why DC loaded with apoptotic bodies are superior in stimulating T cell responses in comparison to other approaches for antigen loading. A simplistic speculation is that apoptotic bodies allow uptake and processing of a larger quantity of antigen than pinocytic vesicles taking up tumor lysate or in vitro transcription of transfected RNA. In dendritic cells, phagocytosis of apoptotic bodies occurs through a complex receptor, including CD36, avb5, or avb3, and signaling through the CrkII-Dock180-rac1 molecular complex, whereas macropinocytosis is a cytoskeletondependent type of fluid-phase endocytosis. 27 Another explanation may be that cell lysates or total RNA extracts may contain large amounts of antigens that are irrelevant to tumor recognition. This may in turn decrease the effectivity of these approaches in stimulating tumor-specific T cell responses. There is very little evidence that apoptotic cells are processed intracellularly or presented through pathways that are different from other antigens, such as necrotic cells. After internalization, most particulate antigens requiring phagocytosis are digested into peptides associated with MHC class II molecules in the endocytic compartments and are presented to T-helper cells. 28 This is believed to be the predominant processing pathway of the cell lysate, while scavenger receptormediated phagocytosis of apoptotic tumor cells allows antigens to gain access to MHC I compartments, resulting in .
DC-based vaccines in B-CLL P Kokhaei et al cross-presentation of antigens to CTLs. 29 A recent report 30 has examined this issue and reports that antigens derived from apoptotic and necrotic pathways are internalized and processed by the same transporter associated with the antigen processing (TAP)-dependent mechanism. There is also evidence that other TAP-independent mechanisms are concurrently ongoing. However, if a specific cellular event triggered by apoptotic bodies is identified in the future as the causative factor for enhancing antigen presentation or immune stimulatory properties of DC, it would be a significant finding in terms of improving the design of DC-based immunotherapeutic strategies.
